In this article
Retatrutide is an investigational peptide that activates three receptors at once: GLP-1, GIP and glucagon. The first two reduce appetite and improve glucose handling, while glucagon signaling raises energy use and shifts the body toward burning stored fat. It is not FDA-approved, and it is discussed here as a research compound.
- Retatrutide is a “triple agonist”: it targets the GLP-1, GIP and glucagon receptors with a single molecule.
- GLP-1 and GIP signaling mainly affect appetite, gastric emptying and insulin response; glucagon signaling adds an energy-expenditure and fat-oxidation effect.
- Reported trial weight loss at the highest doses was larger than what is reported for dual agonists, but the compound remains investigational.
- Most side effects reflect the gut effects of GLP-1 signaling and tend to be strongest while the dose is rising.
What “triple agonist” means
An agonist is a molecule that binds a receptor and switches it on. Natural gut and pancreatic hormones such as GLP-1, GIP and glucagon each act on their own receptors. Retatrutide is engineered to bind all three, so one compound mimics the combined signal of three hormones.
Earlier drugs in this class used one receptor (GLP-1) or two (GLP-1 and GIP). Adding the glucagon receptor is the new element, and it is the reason retatrutide is studied separately from those drugs.
The three pathways
GLP-1 receptor: appetite and glucose
GLP-1 signaling acts on appetite centers in the brain and slows the rate at which the stomach empties. People tend to feel full sooner and stay full longer. It also increases insulin release when glucose is high, which helps explain its effect on blood sugar.
GIP receptor: metabolic coordination
GIP is another gut hormone that stimulates insulin release after a meal. Its role in body weight is less settled than that of GLP-1, and research continues on how it interacts with GLP-1 signaling. It is generally described as complementing the appetite effect and supporting glucose control.
Glucagon receptor: energy use and fat mobilization
Glucagon is best known as the hormone that raises blood sugar between meals. It also promotes the breakdown and oxidation of fat in the liver and may increase energy expenditure. On its own, glucagon signaling would raise glucose, so the concern in drug design is balancing it against the glucose-lowering effect of the other two pathways.
| Receptor | Main role | Likely contribution |
|---|---|---|
| GLP-1 | Satiety, slower gastric emptying, insulin release | Lower food intake |
| GIP | Insulin release, metabolic signaling | Complements GLP-1; glucose control |
| Glucagon | Fat oxidation, possible higher energy expenditure | Greater fat mobilization |
Why combine them?
The working idea is that the pathways cover different parts of the energy balance equation. GLP-1 and GIP reduce the amount of energy taken in. Glucagon adds to the amount spent and changes which fuel the body uses. A drug that does both could, in principle, produce a larger effect than one acting on intake alone.
This is a hypothesis supported by trial data, not a settled mechanism. How much each receptor contributes in people is still being worked out.
What the trials report
In the phase 2 obesity trial published in the New England Journal of Medicine, the highest retatrutide dose produced an average body-weight reduction of 24.2% at 48 weeks. For context, tirzepatide, a dual GLP-1/GIP agonist, has reported averages around 20.9% in its own long-term obesity trial. These were different studies with different populations and durations, so they should not be read as a head-to-head result. A direct comparison is covered in semaglutide vs tirzepatide vs retatrutide.
Claims you may see online about exact muscle-versus-fat ratios, resting metabolic rate increases, or receptor “activation percentages” at specific doses are not backed by the trial publications and should be treated with caution. Body-composition data from these trials are still limited.
Why side effects occur
The common adverse effects follow from the mechanisms above.
- Nausea and other gut effects: linked to slower gastric emptying and central GLP-1 signaling. They are usually most noticeable when the dose is increased.
- Constipation or diarrhea: changes in gut motility and in how much a person eats.
- Heart rate increase: reported with this class of drug and flagged in monitoring guidance. Signal IQ’s retatrutide compound page describes baseline and ongoing checks.
- Fatigue: may relate to a large drop in calorie intake.
Supporting factors discussed in research
Trials of this drug class pair the drug with lifestyle guidance. Protein adequacy and resistance exercise are commonly discussed because any large weight loss includes some lean mass loss, and these habits are the usual way to limit it. Abrupt discontinuation is another recurring topic: appetite often returns after stopping, and weight regain is typical.
To explore compounds that act on related pathways, see peptides by goal or the Signal Library. For a plain-language introduction, start with what are peptides, and for the regulatory distinction see research use vs human use. Questions can also go to Pulse.
Frequently asked questions
How does retatrutide work in simple terms?
It mimics three gut and pancreatic hormones at once. Two of them reduce appetite and support insulin release, and the third, glucagon, increases fat breakdown and energy use.
Is retatrutide FDA-approved?
No. It is an investigational compound and is not approved for human use.
How is retatrutide different from tirzepatide?
Tirzepatide activates GLP-1 and GIP receptors. Retatrutide adds the glucagon receptor, which is expected to contribute through increased energy expenditure and fat oxidation.
Can it cause low blood sugar?
Hypoglycemia is uncommon in people without diabetes with this drug class, but the risk rises when combined with insulin or sulfonylureas. Anyone using glucose-lowering medication needs clinician oversight.
Why is nausea so common?
GLP-1 signaling slows stomach emptying and acts on brain pathways that regulate nausea and fullness. It is usually most pronounced during dose increases.
What happens after stopping?
With this drug class, appetite generally returns once the drug is cleared and weight regain is common. Do not assume that metabolic benefits persist unchanged.
References
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial, N Engl J Med — pubmed.ncbi.nlm.nih.gov
Go deeper on Signal IQ
Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.
Ask PulseEducational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.



